Johns Hopkins Medicine is leading an innovative approach in the fight against Alzheimer’s disease by testing implantable “brain pacemakers” designed to stimulate key memory-related circuits in the brain. Unlike conventional treatments that rely on medication, this experimental technique uses deep brain stimulation (DBS) to deliver approximately 130 low-voltage electrical pulses per second, with the goal of preserving brain activity and slowing cognitive decline.

The devices are surgically implanted to target the fornix, a critical bundle of nerve fibers that connects to the hippocampus, the brain region essential for memory formation and learning. In Alzheimer’s disease, the hippocampus is one of the first areas to deteriorate, leading to progressive memory loss and impaired thinking. By directly stimulating the fornix, researchers hope to activate neural pathways that are weakened by the disease and help maintain communication within the brain’s memory network.

Early evidence supporting this approach comes from clinical studies conducted in Canada, where patients with mild Alzheimer’s disease received deep brain stimulation targeting the same region. Results showed that these patients maintained higher levels of glucose metabolism in certain brain areas for more than a year compared to those who did not receive stimulation. Glucose metabolism is a widely used indicator of active and healthy brain cells, suggesting that DBS may help slow the functional decline associated with Alzheimer’s.

This strategy represents a significant departure from traditional drug-based therapies. Most Alzheimer’s medications aim to alter chemical processes in the brain, such as reducing amyloid-beta plaques or modifying neurotransmitter levels. In contrast, deep brain stimulation bypasses chemical targets altogether, directly activating neural circuits involved in memory and cognition. Researchers believe this circuit-based approach may be especially valuable given the limited success of many drug treatments in halting disease progression.

At present, eligibility for the procedure is restricted. Only patients with mild cognitive impairment or early-stage Alzheimer’s disease, and who are still able to provide informed consent, can participate in ongoing trials. This cautious approach reflects both ethical considerations and scientific evidence suggesting that earlier intervention may be more effective. Once extensive neuronal damage has occurred, stimulating weakened circuits may offer limited benefit.

Looking ahead, scientists hope that applying deep brain stimulation at even earlier stages could help preserve brain function for longer periods, potentially delaying the most debilitating symptoms of Alzheimer’s disease. While the technique is still experimental and not without risks, it highlights a growing shift in neuroscience toward treating brain disorders by modulating neural networks rather than relying solely on pharmaceuticals. If successful, brain pacemakers could become a powerful new tool in the effort to combat one of the world’s most challenging neurodegenerative diseases.